This company seems to have been delisted
Reason: Acquired by Bristol Myers Squibb
Last recorded trade on: March 26, 2024
Source: https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-mirati-acquisition/
Reason: Acquired by Bristol Myers Squibb
Last recorded trade on: March 26, 2024
Source: https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-mirati-acquisition/
Mirati Therapeutics
MRTX
$58.70
Share price
0.00%
Change (1 day)
48.95%
Change (1 year)
Categories
Mirati Therapeutics (MRTX) Fails to deliver data
Key failure to deliver metrics for Mirati Therapeutics:
- Last SEC data release: 2024-12-31
- Last 15 days FTD volume: N/A
- Last 3 months FTD volume: N/A
- Last year FTD volume: N/A
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Mirati Therapeutics (MRTX) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Mirati Therapeutics (MRTX) - since 2013
Volume in USD (price x number of shares), data since 2013Mirati Therapeutics (MRTX) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2024 | $6.73 M | -49.4% |
| 2023 | $13.31 M | -77.91% |
| 2022 | $60.27 M | 32.3% |
| 2021 | $45.55 M | 8.14% |
| 2020 | $42.12 M | -28.18% |
| 2019 | $58.66 M | 69.74% |
| 2018 | $34.56 M | 124.1% |
| 2017 | $15.42 M | 184.96% |
| 2016 | $5.41 M | 6.38% |
| 2015 | $5.08 M | 38.88% |
| 2014 | $3.66 M | 32.7% |
| 2013 | $2.76 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 TravelCenters of America TA | N/A | $4.02 M | 🇺🇸 USA |
 Nymox Pharmaceutical NYMX | $0.03 M | $0.2 M | Bahamas |